Opposing effects of tumor necrosis factor receptor 1 and 2 in sepsis due to cecal ligation and puncture

被引:61
作者
Ebach, DR
Riehl, TE
Stenson, WF
机构
[1] Washington Univ, Dept Pediat, Div Pediat Gastroenterol, St Louis, MO USA
[2] Washington Univ, Dept Internal Med, Div Gastroenterol, St Louis, MO USA
来源
SHOCK | 2005年 / 23卷 / 04期
关键词
tumor necrosis factor-alpha; tumor necrosis factor receptor; sepsis; cecal ligation and puncture; apoptosis; cytokines;
D O I
10.1097/01.shk.0000157301.87051.77
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Tumor necrosis factor (TNF)-alpha, a cardinal molecule in the cascade of sepsis-induced host injury, binds to two distinct receptors: tumor necrosis factor receptor (TNFR) 1 and TNFR2. We used the cecal ligation and puncture model of polymicrobial sepsis to elucidate the role of these receptors in sepsis pathogenesis. Mice lacking TNFR1 had prolonged survival with less hypothermia, whereas mice lacking TNFR2-/- had shortened survival and more profound hypothermia than wild-type mice. TNFR1-/- and TNFR2-/- mice had increased serum concentrations of interleukin (IL) 10 and total TNF-alpha (free plus receptor bound) compared with wild-type mice, but there were no differences in IL6 or IL10 concentrations. Furthermore, free TNF-alpha was markedly elevated in the serum and peritoneal fluid of mice lacking TNFR2, supporting a role for this receptor in regulating the concentration of TNF-alpha. Lastly, apoptosis of ileal crypt epithelial cells was increased in mice lacking TNFR1, but there were no differences in lymphocyte apoptosis. These data suggest that in sepsis, TNFR1 mediates much of the TNF-alpha-induced pathology, whereas TNFR2 mediates protective effects.
引用
收藏
页码:311 / 318
页数:8
相关论文
共 31 条
[1]   EFFICACY AND SAFETY OF MONOCLONAL-ANTIBODY TO HUMAN TUMOR-NECROSIS-FACTOR-ALPHA IN PATIENTS WITH SEPSIS SYNDROME - A RANDOMIZED, CONTROLLED, DOUBLE-BLIND, MULTICENTER CLINICAL-TRIAL [J].
ABRAHAM, E ;
WUNDERINK, R ;
SILVERMAN, H ;
PERL, TM ;
NASRAWAY, S ;
LEVY, H ;
BONE, R ;
WENZEL, RP ;
BALK, R ;
ALLRED, R ;
PENNINGTON, JE ;
WHERRY, JC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (12) :934-941
[2]   The tumor necrosis factor ligand and receptor families [J].
Bazzoni, F ;
Beutler, B .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (26) :1717-1725
[3]   Sepsis and cytokines: Current status [J].
Blackwell, TS ;
Christman, JW .
BRITISH JOURNAL OF ANAESTHESIA, 1996, 77 (01) :110-117
[4]   INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis [J].
Cohen, J ;
Carlet, J .
CRITICAL CARE MEDICINE, 1996, 24 (09) :1431-1440
[5]   Overexpression of Bcl-2 in the intestinal epithelium improves survival in septic mice [J].
Coopersmith, CM ;
Chang, KC ;
Swanson, PE ;
Tinsley, KW ;
Stromberg, PE ;
Buchman, TG ;
Karl, IE ;
Hotchkiss, RS .
CRITICAL CARE MEDICINE, 2002, 30 (01) :195-201
[6]   Medical progress: Hereditary periodic fever. [J].
Drenth, JPH ;
van der Meer, JWM .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (24) :1748-1757
[7]  
ECHTENACHER B, 1990, J IMMUNOL, V145, P3762
[8]   Tumor necrosis factor-dependent adhesions as a major protective mechanism early in septic peritonitis in mice [J].
Echtenacher, B ;
Weigl, K ;
Lehn, N ;
Männel, DN .
INFECTION AND IMMUNITY, 2001, 69 (06) :3550-3555
[9]  
ESKANDARI MK, 1992, J IMMUNOL, V148, P2724
[10]   Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein [J].
Fisher, CJ ;
Agosti, JM ;
Opal, SM ;
Lowry, SF ;
Balk, RA ;
Sadoff, JC ;
Abraham, E ;
Schein, RMH ;
Benjamin, E .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (26) :1697-1702